Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Net Cash Flow (2024 - 2025)

Evommune (EVMN) has disclosed Net Cash Flow for 2 consecutive years, with $17.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 1012.11% to $17.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.4 million, a N/A change, with the full-year FY2025 number at $29.0 million, up 327.23% from a year prior.
  • Net Cash Flow was $17.2 million for Q4 2025 at Evommune, up from -$1.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $17.2 million in Q4 2025 to a low of -$1.9 million in Q4 2024.